/term/receipts-from-government-grants/FRA:2B30 Xeris Biopharma Holdings (FRA:2B30) Receipts from Governmen
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (FRA:2B30) » Definitions » Receipts from Government Grants

Xeris Biopharma Holdings (FRA:2B30) Receipts from Government Grants


View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Receipts from Government Grants?

Receipts from Government Grants only applicable to companies reporting Cash Flow from Operations in direct method.

Xeris Biopharma Holdings (FRA:2B30) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (FRA:2B30) » Definitions » Receipts from Government Grants
Comparable Companies
YMAB DRTS CMPX CELC ACIU IGMS NUVB ARQT ZURA OVID OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
XERS:USA 0A8E:UK
Address
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Website
https://www.xerispharma.com
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.